Expanding and Collapsing Scalar Field Thin Shell

This paper deals with the dynamics of scalar field thin shell in the Reissner-Nordstr$\ddot{o}$m geometry. The Israel junction conditions between Reissner-Nordstr$\ddot{o}$m spacetimes are derived, which lead to the equation of motion of scalar field shell and Klien-Gordon equation. These equations are solved numerically by taking scalar field model with the quadratic scalar potential. It is found that solution represents the expanding and collapsing scalar field shell. For the better understanding of this problem, we investigate the case of massless scalar field (by taking the scalar field potential zero). Also, we evaluate the scalar field potential when $p$ is an explicit function of $R$. We conclude that both massless as well as massive scalar field shell can expand to infinity at constant rate or collapse to zero size forming a curvature singularity or bounce under suitable conditions.Comment: 15 pages, 11 figure

Optimising antifungal prophylaxis in allogeneic stem cell transplantation - a cohort study of two different approaches

Published online December 2022Background: Limited consensus exists on the optimal use of antifungal agents to prevent invasive fungal infection in the early post allogeneic hematopoietic stem cell transplant (alloHCT) period, particularly when patients cannot tolerate oral medication administration. Methods: We undertook a retrospective observational cohort study to assess the tolerability, efficacy, and cost of a new antifungal prophylaxis pathway at a major tertiary alloHCT centre. Patients aged ≥16 years who underwent alloHCT between February 2018 and October 2019 (cohort 1) or between April 2020 and November 2021 (cohort 2) were included. In both cohorts, first line prophylactic therapy was oral posaconazole. The second line drugs where oral therapy was unable to be administered were intravenous voriconazole (cohort 1) versus intravenous posaconazole (cohort 2). Results: There were 142 patients enrolled in the study, 71 in each cohort. The proportion of patients remaining on first-line prophylaxis or progressing to second-, third-, and fourth-line options was 22.5%, 39.4%, 29.6%, and 8.5% in cohort 1 and 39.4%, 59.2%, 1.4%, and 0% in cohort 2, respectively. The frequency of neuropsychiatric adverse events was significantly higher in cohort 1 compared to cohort 2 (49.3% vs. 19.8%, p = .0004). Occurrence of proven and probable fungal infections was not significantly different between cohorts. Antifungal drug expenditure was $359 935 (AUD) more in cohort 1 ($830 486 AUD) compared to cohort 2 ($477 149 AUD). Conclusion: The antifungal prophylaxis pathway used in cohort 2 resulted in reduced antifungal-associated adverse effects, less patients requiring progression to 3rd and 4th line prophylaxis and reduced antifungal drug costs.Philip R. Selby, Morgyn S. Warner, Sandra L. Peake, Peter Bardy, Devendra Hiwase, Deepak Singhal, Ashanka Beligaswatte, Uwe Hahn, Jason A. Roberts, David Yeung, Sepehr Shaki